To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation.
INTRODUCTION
Multiple myeloma (MM) is a malignant neoplasm that affects primarily elderly patients. 1, 2 During the past decade, considerable progress has been made in the management of MM, prompting the International Myeloma Working Group (IMWG) to develop these updated guidelines.
Staging and Prognostic Factors
The International Staging System (ISS) is used to assess the prognosis of patients with symptomatic MM (Appendix Table A2 , online only). 17 ISS stage III is associated with poor prognosis. Chromosomal abnormalities t(4;14), t(14;16), and t(14;20); chromosome 1 abnormalities; and del17p detected by fluorescent in situ hybridization (FISH) are associated with poor prognosis, [18] [19] [20] [21] whereas the isolated 13q deletion is not considered a high-risk feature. Hyperdiploidy, t(11;14), and t(6;14) are considered Both criteria must be met: Serum monoclonal protein (IgG or IgA) Ն 3 g/100 mL and/or clonal bone marrow plasma cells Ն 10% Absence of myeloma-related organ damage (CRAB) that can be attributed to plasma-cell proliferative disorder MM (symptomatic)
All three criteria must be met: Clonal bone marrow plasma cells Ն 10%
standard-risk features. The combination of FISH data with ISS stage improves risk assessment. 20 An abnormal / FLC ratio at diagnosis seems to predict poor prognosis. 22 Gene expression profiling (GEP) is emerging as a predictive tool to further refine risk stratification. 23, 24 The prognostic role of PET/CT has been recently investigated in transplantation-eligible patients, 25 although a standardization of this procedure is needed to translate its use into clinical practice. The achievement of complete response (CR) after initial treatment is associated with improved progression-free (PFS) and overall survival (OS).
26,27
Recommendations:
• The ISS should always be used at diagnosis (grade C/IV).
• Chromosomal abnormalities should be detected to predict outcome (grade C/IV).
• New prognostic markers (FLC, GEP, and PET/CT) need additional evaluations (grade C/IV).
Indications for Treatment
For asymptomatic patients, close monitoring is suggested every 1 to 3 months. Clinical trials are currently evaluating the role of early therapy with novel agents in high-risk asymptomatic myeloma. 28 Conversely, patients with active and symptomatic MM, defined by the presence of CRAB symptoms, require immediate treatment.
Second-line treatment is indicated when there is either a clinical relapse (reoccurrence of CRAB symptoms) or a significant and quick paraprotein increase (doubled monoclonal protein within 2 months, with an increase in the absolute levels of monoclonal protein of Ն 1g/dL in serum or of Ն 500 mg per 24 hours in urine confirmed by two consecutive measurements). 29 Whether to start treatment in case of biochemical relapse (25% increase in the paraprotein from the lowest response value without CRAB symptoms) is an open issue.
Recommendations: • Asymptomatic patients should be carefully monitored every 1 to 3 months (grade C/IV).
• Initial therapy is indicated when CRAB symptoms occur (grade C/IV).
• Re-treatment is indicated in case of clinical relapse or if the paraprotein has doubled within 2 months (grade C/IV).
Definition of Response to Therapy
The uniform response criteria were recently revised by the IMWG (Table 3) . 29 , 30 The definitions of immunophenotypic CR, molecular CR, and FLC response were introduced to refine the depth of response. MRI and PET/CT have not been incorporated into the response criteria assessment. Recommendation: • The updated IMWG criteria (Table 3) should be used to assess response every 30 to 60 days during treatment (grade C/IV).
29

Front-Line Therapy
Patients age 65 to 75 years are generally considered ineligible for autologous stem-cell transplantation (ASCT). Because biologic age can differ from chronologic age, this strict range may differ by approximately 5 years.
Different therapeutic approaches may be adopted according to age and patient status (Table 4) . For patients age 65 to 70 years in excellent clinical condition (very fit), or younger patients with comorbidities, a reduced dose-intensity ASCT with melphalan 100 mg/m 2 (MEL100) can be safely adopted instead of full-dose melphalan 200 mg/m 2 (MEL200). For patients age 65 to 75 years in good clinical condition (fit), full-dose conventional chemotherapy is indicated, whereas for frail patients age Ͼ 75 years (unfit), or younger patients with comorbidities, reduced dose-intensity therapy is suggested.
The choice of treatment should take into account patient status (Fig 1) , the risk/benefit ratio of each regimen (Table 5) , and patient quality of life. Patients with newly diagnosed myeloma should be referred to specialized units to receive appropriate care (Appendix, online only).
Reduced-Intensity Autologous Transplantation
In patients age 65 to 70 years, MEL100 followed by ASCT was superior to standard melphalan-prednisone (MP), improving both event-free survival (28 v 16.4 months) and OS (58 v 37.2 months), 55 but in patients age 65 to 75 years, MEL100 was inferior to MP-thalidomide (MPT; PFS, 19.4 v 27.5 months). 31 In patients age 65 to 75 years, bortezomib-based induction, tandem MEL100, lenalidomideprednisone consolidation, and lenalidomide maintenance led to a median PFS of approximately 4 years. 56 In selected very fit patients, ASCT remains feasible well beyond the age limit of 65 years. As recommended for patients age Ͻ 65 years, bortezomib-based induction and lenalidomide maintenance should be considered for patients undergoing ASCT.
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Recommendation:
• Very fit patients age 65 to 75 years, unsuitable for MEL200, may benefit from MEL100 (grade B/IIa). Median, 15.6 months Abbreviations: CR, complete response; CTDa, cyclophosphamide-thalidomide-dexamethasone; D, dexamethasone; EFS, event-free survival; FISH, fluorescent in situ hybridization; MPR, melphalan-prednisonelenalidomide; MPT, melphalan-prednisone-thalidomide; OS, overall survival; PFS, progression-free survival; R, lenalidomide; Rd, lenalidomide plus low-dose dexamethasone; RD, lenalidomide plus high-dose dexamethasone; TTP, time to progression; V, bortezomib; V-Peg, bortezomib plus pegylated liposomal doxorubicin; VCD, bortezomib, cyclophosphamide, and dexamethasone; VGPR, very good partial response;
VMP, bortezomib-melphalan-thalidomide; VMPT, bortezomib-melphalan-prednisone-thalidomide; VTP, bortezomib-thalidomide-prednisone.
‫ء‬
For both patients enrolled in VTP or VMP arms; study detected no significant difference between two treatment arms (VMP v VTP). †Immunofixation-negative CR plus immunofixation-positive CR. ‡With or without transplantation. ʈPatients with adverse interphase FISH receiving thalidomide showed no significant PFS benefit and worse OS (P
Thalidomide-Based Regimens
Thalidomide combined with dexamethasone (TD) was superior to high-dose dexamethasone for partial response (63% v 41%) 58 and time to progression (TTP; 22.6 v 6.5 months) 59 but was more toxic. Similarly, TD was superior to MP for responses, but PFS was similar, and OS was shorter. 60 Six randomized studies compared MPT with standard MP. Despite differences in doses and schedules among the trials, better responses and PFS were reported with MPT.
31,32,49-53 The effect on OS varied across the studies, and only two trials showed a significant survival benefit.
31, 52 In a meta-analysis of data from 1,682 patients, MPT improved PFS by 5.4 months and OS by 6.6 months. 33 Severe adverse events (AEs), especially nonhematologic, were higher with MPT and negatively affected the prognosis. 53 Thalidomide-related AEs included cytopenia, thrombosis, fatigue, and peripheral neuropathy.
Cyclophosphamide-thalidomide-dexamethasone improved responses compared with MP, with similar survival outcomes and higher incidence of AEs. 34 Thalidomide doses Ͼ 100 mg per day are poorly tolerated and not appropriate for elderly patients. MPT has the advantage of oral administration and reduced hematologic toxicity, but it is associated with an increased risk of peripheral neuropathy, deep-vein thrombosis, and cardiac events. The use of this combination is supported by different phase III trials.
Bortezomib-Based Regimens
In a large phase III trial, the addition of bortezomib to standard MP (VMP) significantly increased CR from 4% to 30%, TTP by approximately 7 months, and OS by 13 months.
35,61 Bortezomibrelated AEs included primarily neutropenia, thrombocytopenia, and peripheral neuropathy. 62 When the twice-per-week bortezomib ; MPR-R, melphalanprednisone-lenalidomide followed by lenalidomide; MPT, melphalan-prednisonethalidomide; Rd, lenalidomide plus lowdose dexamethasone; Vd, bortezomibdexamethasone; VCD, bortezomibcyclophosphamide-dexamethasone; VMP, bortezomib-melphalanprednisone; VMPT-VT, bortezomibmelphalan-p r e d n i s o n ethalidomide followed by bortezomib-thalidomide; VRD, bortezomib-lenalidomidedexamethasone. schedule was decreased to once per week, the rate of grade 3 to 4 peripheral neuropathy was significantly reduced from 28% to 8%, without affecting efficacy. 38, 54 Recently, subcutaneous bortezomib proved to be as effective as intravenous administration, with a reduced risk of peripheral neuropathy.
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The four-drug combination of bortezomib, melphalan, prednisone, and thalidomide followed by continuous bortezomibthalidomide (VMPT-VT) demonstrated better responses and a PFS prolongation of 8 months compared with VMP, but the efficacy advantage was mainly reported in fit patients 65 to 75 years of age.
36,37
Bortezomib-thalidomide-prednisone (VTP) as induction, followed by VT or bortezomib-prednisone, was not superior to VMP and was associated with more serious AEs and discontinuations. 38 Promising results were obtained when cyclophosphamide (VCD) 39, 40 or lenalidomide (VRD) 41 were combined with bortezomibdexamethasone (VD), producing high-quality responses. Bortezomib, either intravenously or subcutaneously, induces high and rapid responses. Bortezomib does not increase the risk of thromboembolism and may be used in patients with renal failure, but peripheral neuropathy and thrombocytopenia are the main dose-limiting toxicities. The benefits of VMP and VMPT-VT are supported by phase III trials; alternatively, VCD or VRD can be adopted.
Lenalidomide-Based Regimens
The combination lenalidomide plus low-dose dexamethasone (Rd) was better tolerated than lenalidomide plus high-dose dexamethasone (RD), with a significant survival benefit (2-year OS, 87% v 75%). The most common grade Ն 3 AEs were thrombosis, infections, and fatigue and were more frequent with RD.
42
Melphalan-prednisone-lenalidomide followed by lenalidomide (MPR-R) significantly prolonged median PFS by 17 months in comparison with fixed-duration melphalan-prednisone-lenalidomide (MPR) and by 18 months compared with MP. However, this advantage was not confirmed in patients age Ͼ 75 years. During induction, the most frequent AEs were hematologic. The incidence rates per 100 patient-years of hematologic second primary malignancies (SPMs) were 1.92, 1.30, and 0.40 in the MPR-R, MPR, and MP groups, respectively, whereas solid SPMs were heterogeneous and balanced across arms. 43 Lenalidomide has the advantage of the oral administration and the lack of neurologic toxicity, although myelosuppression is common, and the prevention of venous thromboembolism is recommended. MPR-R is supported by a phase III trial, whereas the evaluation of Rd compared with melphalan-based regimens is ongoing.
Recommendations: • Fit patients should receive full-dose therapy. MPT, VMP, Rd, VMPT-VT, and MPR-R are reasonable therapeutic options (grade A/Ib).
• MPT may be preferred for its oral administration and lower cost (grade C/IV).
• VMP and VMPT-VT or VCD and VRD may be preferred in patients who need rapid, profound cytoreduction. Once-perweek subcutaneous bortezomib should be considered because of the lower incidence of AEs (grade C/IV).
• Rd or MPR-R may be preferred when oral administration and the lack of peripheral neuropathy are major considerations (grade C/IV).
Treatment Options for Unfit Patients
Unfit patients are more susceptible to AEs with subsequent treatment discontinuations that significantly affect dose-intensity and efficacy. In these patients, lower dose-intense therapies are suggested. The three-drug combination MPT has consistently showed a PFS improvement that was less pronounced in patients age Ͼ 75 years, whereas VMP was superior to MP in patients age Ͼ 75 years.
35,52,61 In a randomized study, the outcome was similar between VD, VMP, and VT-dexamethasone, but the discontinuation rate was lower with VD. 64 The combination Rd was equally effective in younger and elderly patients. Therefore, two-drug combinations such as corticosteroid plus lenalidomide, thalidomide, or bortezomib should be considered safe treatment options for unfit patients.
64-67
Low-dose dexamethasone is mandatory because of the higher toxicity and mortality rates associated with high-dose dexamethasone. 42 Lower doses of dexamethasone (10-20 mg/wk) are better tolerated. Thalidomide at 50 mg per day and lenalidomide at 15 mg per day are the preferred doses in this setting.
52,68 Subcutaneous once-perweek bortezomib 1 mg/m 2 is highly suggested in unfit patients.
38,54,63
Because the risk of AEs is higher at the beginning of treatment, therapy may be started at lower doses and subsequently increased after 2 to 4 months if tolerated or if the disease is not adequately controlled.
Recommendation: • Unfit patients should receive reduced-dose MPT or VMP or two-drug combinations with bortezomib or lenalidomide and low-dose dexamethasone (ie, Vd or Rd; grade C/IV).
Maintenance Therapy
Maintenance treatment has consistently prolonged PFS but has inconsistently improved survival.
44, 69 In a recent meta-analysis, continuous thalidomide improved PFS, with a late OS benefit. 44 In another meta-analysis, lenalidomide reduced the risk of progression by 65% in both young and elderly patients. 70 In the MRC Myeloma IX trial, the longest PFS was reported in patients treated with thalidomide both at induction and after induction; the shortest PFS was seen in the group treated with MP without thalidomide. 44 Continuous thalidomide showed no PFS benefit and worse OS in patients with adverse FISH.
In a prespecified landmark analysis of the MM015 trial, continuous lenalidomide significantly extended PFS from the start of lenalidomide (26 months) as compared with placebo (7 months), regardless of age. 43 Similarly, VT prolonged median PFS by approximately 14 months. 37 Continuous therapy with VT or bortezomibprednisone led to a median PFS of 30 months versus 24 months, respectively.
71
Drug-related toxicity associated with continuous thalidomide therapy may limit its long-term administration. Lenalidomide is well tolerated, although it is also associated with a higher risk of SPMs. Continuous treatment with bortezomib has the inconvenience of injection administration and a slight increased risk of peripheral neuropathy.
In the future, the impact of maintenance on response and outcome after progression needs to be clarified. Similarly, the optimal duration of maintenance should be defined (for a fixed duration of 2 years or until progression/intolerance).
Recommendations: • The routine use of maintenance in transplantation-ineligible patients is not yet validated.
• Thalidomide is an option for standard-risk patients, although its long-term use is limited by the risk of peripheral neuropathy (grade A/Ib).
• Lenalidomide is well tolerated but associated with a higher risk of SPMs (grade A/Ib).
• Bortezomib can be an effective alternative, with lower risk of peripheral neuropathy than thalidomide (grade B/IIa).
Therapy for Relapsed Disease
When treating patients with relapsed myeloma, duration of response to previous therapy is a fundamental factor to consider. Repeating the same treatment is a valuable option for patients with a durable response lasting more than 20 to 24 months after induction at diagnosis and more than 9 to 12 months after therapy at relapse. In the case of short-term remission duration or progression during initial therapy, an alternative regimen is suggested.
Standard treatments include bortezomib or lenalidomide combined with dexamethasone or bortezomib-pegylated liposomal doxorubicin. [45] [46] [47] 72, 73 Rd is highly suggested because it is better tolerated compared with RD.
Re-treatment with bortezomib is a feasible option. 74 Reexposure to immunomodulatory drugs such as lenalidomide after previous thalidomide seems feasible; however, efficacy and survival may be lower. 75, 76 In case of stable disease without CRAB symptoms, the treatment strategy should not be changed. The asymptomatic status, rather than a response improvement, is the most relevant factor to consider during salvage treatment. 77 In case of biochemical relapse, especially during maintenance therapy, increasing the dose of the current drug and subsequently adding another agent is a sensible strategy.
In a recent survey, poor outcome was reported once patients became refractory to both bortezomib and immunomodulatory drugs. 78 Ongoing trials are exploring novel agents, such as new proteasome inhibitors (carfilzomib combined with lenalidomidedexamethasone), anti-CS1 monoclonal antibody (elotuzumab plus lenalidomide-dexamethasone or VD), histone-deacetylase inhibitors (panobinostat and vorinostat), and bendamustine. The US Food and Drug Administration recently approved carfilzomib for progressive MM after at least two prior therapies, including bortezomib and immunomodulatory agents, and pomalidomide in patients relapsed/ refractory to lenalidomide. 48, 79 Thalidomide is preferred for its limited hematologic toxicity; bortezomib is preferred in case of renal failure or previous deep-vein thrombosis; lenalidomide is suggested in case of concomitant peripheral neuropathy. Palliative care is essential when cure is no longer possible (Appendix, online only).
Recommendations: • Repeating the same treatment should be considered after long-lasting remission (20-24 months); an alternative regimen is suggested for patients with shorter remission duration (9 to 12 months; grade C/IV).
• VD or bortezomib-pegylated liposomal doxorubicin and lenalidomide-dexamethasone are the treatments of choice (grade A/Ib).
Bone Disease
Bone disease is a highly disabling event that can cause pain, pathologic fractures, spinal cord compression, and hypercalcemia. 80 Pain requires pharmacologic analgesia, together with chemotherapy, bisphosphonates, and local interventions. 81 Radiotherapy may be useful to prevent further osteolysis at the fracture site; percutaneous vertebroplasty and balloon kyphoplasty are suggested in case of painful spinal fractures.
Oral clodronic acid, intravenous pamidronic acid, and zoledronic acid are the available bisphosphonate treatments.
82-84 Zoledronic acid significantly reduced skeletal-related events (SREs) and improved OS compared with sodium clodronate. 85, 86 Zoledronic acid was as effective as pamidronate in preventing SREs. 87, 88 No difference was observed between monthly pamidronate at 30 or 90 mg. 89 Renal impairment and osteonecrosis of the jaw are infrequent but serious complications of intravenous bisphosphonates.
Recommendations: • Analgesics should be used to treat uncontrolled pain. Lowdose radiation therapy (8 Gy, single fraction) of limited involved fields should be used in case of pain not responding to therapy. Vertebroplasty and kyphoplasty should be considered for painful vertebral collapse (grade C/IV).
• Amino-containing bisphosphonates are recommended for the prevention and management of SREs, independently of bone disease status at baseline. Renal function should be carefully monitored, drug doses should be reduced, and dental evaluation should be performed before starting therapy (grade A/Ib). There is insufficient evidence to recommend bisphosphonates in asymptomatic MM.
Renal Failure
Renal failure occurs because of FLC-related damage of proximal tubules, along with hypercalcemia, hyperuricaemia, dehydration, infections, and nephrotoxic drugs. The immediate start of an effective MM treatment is the mainstay to recover renal function. High-dose dexamethasone is a rapid intervention to assure a fall in light chain load. 90 Bortezomib can be administered safely, without dose adjustments, and should be preferred in the event of dialysis. [91] [92] [93] [94] [95] Limited data are present on the role of thalidomide in this setting. 96, 97 Lenalidomide is active, 98,99 but dose reductions are mandatory depending on the creatinine clearance values. 100,101 Doxorubicin and cyclophosphamide do not require dose adjustments. Adjusted doses of bisphosphonates are indicated to correct hypercalcemia. Additional studies of the new large-pore hemodialysis membranes to physically remove light chains are awaited.
Recommendations: • High-dose dexamethasone (40 mg per day for 4 days) should be started promptly, along with high fluid intake (Ն 3 L per day of saline solution; grade C/IV).
• In case of acute renal failure or for patients requiring dialysis, bortezomib can be safely used without dose modifications (grade C/IV).
• In case of chronic renal impairment, thalidomide and lenalidomide can be administered. Appropriate lenalidomide dose reductions are mandatory: 10 mg per day when creatinine clearance is 30 to 50 mL/min; 15 mg every other day when creatinine clearance is Ͻ 30 mL/min; 5 mg per day after dialysis when patient requires dialysis (grade C/IV).
treatments, and neutrophil count Ͻ 1,000 cells/mL at baseline are additional risk factors of severe neutropenia. Granulocyte colonystimulating factor (G-CSF) should be used to permit patients to stay on treatment longer. 102,103 Anemia can be managed in the short term with transfusions. Erythropoiesis-stimulating agents are indicated during chemotherapy, particularly with renal impairment, when the hemoglobin concentration is Ͻ 10 g/dL, and there is no improvement despite response to therapy. [104] [105] [106] Thrombocytopenia is common with bortezomib, lenalidomide, and alkylating agents, whereas it rarely occurs with thalidomide.
103
• G-CSF is recommended to prevent febrile neutropenia in patients at high risk based on age, medical history, disease characteristics, and the expected myelotoxicity of chemotherapy.
• When grade 3 to 4 neutropenia occurs during chemotherapy, G-CFS should be added. If neutrophil count restores to Ͼ 1,000 cells/mL, therapy can be resumed without dose modifications. If neutrophil count remains Ͻ 1,000 cells/mL, treatment should be delayed until neutrophils recovery and resumed at reduced doses (grade C/IV).
• Patients with hemoglobin Ͻ 10 g/dL during chemotherapy should receive erythropoietin, which should be stopped if an increase of hemoglobin Ն 1 g/dL after 4 weeks of treatment is not obtained (grade A/Ib). Iron supplementation is recommended if transferrin saturation is inadequate.
• If grade 4 thrombocytopenia occurs, treatment should be withheld; it can be resumed when the event resolves to grade 2 (grade C/IV).
Thromboembolism
Myeloma has a high risk of venous thromboembolism (VTE).
107
Patient-related risk factors include advanced age, history of VTE or inherited thrombophilia, obesity, comorbidities, central venous catheter in situ, immobility, and surgery. Myeloma-related factors include the diagnosis of myeloma itself, disease burden, and hyperviscosity. Treatment-related factors include the use of thalidomide or lenalidomide, particularly when combined with high-dose steroids or doxorubicin or multiagent chemotherapy, and the concomitant use of erythropoietin.
108-110
The role of low-molecular weight heparin (LMWH) in preventing VTE is well recognized; aspirin (ASA) should be used in selected circumstances, and fixed low-dose warfarin has generally been shown to be ineffective. 111, 112 The American College of Chest Physicians guidelines recommend LMWH or low-dose unfractionated heparin in outpatients with tumors and risk factors for VTE, including thalidomide and lenalidomide therapy. 
Recommendations:
• Patients with MM should receive appropriate thromboprophylaxis based on risk factors for the first 4 to 6 months of treatment, until disease control is achieved or as long as the risk of thromboembolism remains high (grade C/IV).
• During thalidomide or lenalidomide treatment, ASA should be administered to low-risk patients (with Յ one risk factor). High-risk patients (with Ն two risk factors) should receive prophylactic LMWH or dose-adjusted therapeutic warfarin for 4 to 6 months followed by ASA (grade B/IIa) • The dose of LMWH should be adjusted according to renal function (grade C/IV).
Infections
MM can cause impairment of immune function, with consequent increased risk of infections, particularly during active disease, or treatment with high-dose dexamethasone, myelotoxic agents, or multidrug combinations.
114,115 Herpes zoster is a possible complication related to bortezomib administration.
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Recommendations:
• For unfit patients with comorbidities and for patients with an increased infection rate, oral antibiotic prophylaxis should be considered for the first 3 months of therapy. Trimethoprimsulfamethoxazole prophylaxis should be considered at least during the first 2 to 3 months of chemotherapy or steroid administration (grade C/IV) • Antiviral prophylaxis, such as acyclovir or valacyclovir, is recommended against zoster reactivation during bortezomib treatment and for 30 to 60 days after its discontinuation (grade C/IV).
• Patients with MM should be treated promptly with broadspectrum antibiotics in case of fever or suspected infections (grade C/IV).
Peripheral Neuropathy
Peripheral neuropathy can be caused by the disease itself or by thalidomide and bortezomib therapy. Because treatment-emergent peripheral neuropathy is related to the duration of drug exposure and is cumulative, 116,117 early reduction or temporary discontinuation of the drug should be adopted. 118, 119 Subcutaneous and weekly bortezomib infusions significantly reduced peripheral neuropathy, without considerably affecting outcome. 116 Neuropathic pain is often poorly responsive to standard analgesia, but gabapentin and opioid drugs may improve symptoms.
120-122
• Close monitoring of patients receiving bortezomib and thalidomide is highly recommended. Patients should be informed about the risk of peripheral neuropathy and instructed to promptly seek medical advice when symptoms emerge. When grade 1 peripheral neuropathy with pain or grade Ն 2 occur, treatment should be interrupted until resolution of symptoms and reinitiated at lower doses (grade C/IV).
• Prompt thalidomide dose reductions (from 100 to 50 mg per day) are essential to avoid irreversible damage (grade C/IV).
• Once-per-week bortezomib at a dose of 1.3 mg/m 2 should be reduced to 1.0 mg/m 2 and subsequently to 0.7 mg/m 2 per week (grade C/IV). 
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